VA
RGC icon

Vident Advisory’s Regencell Bioscience RGC Stock Holding History

Vident Advisory’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$752K Sell
29,588
-346
-1% -$9.79K 0.01% 1013
2025
Q4 		$629K Buy
29,934
+11,866
+66% +$193K 0.01% 1030
2025
Q3 		$279K Buy
+18,068
New +$259K ﹤0.01% 1429

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Vident Advisory's RGC Position: Q1 2026 in Review

Vident Advisory reduced its Regencell Bioscience (RGC) stake by 1.2% in Q1 2026, selling an estimated $9.79K and leaving 29,588 shares worth $752K. The position accounts for 0.01% of the portfolio, ranked #1013.

Vident Advisory first reported a position in RGC in Q3 2025 and has held it in 3 quarters since. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Vident Advisory held 29,588 shares of Regencell Bioscience worth $752K as of Q1 2026.
  • Vident Advisory sold 346 Regencell Bioscience shares in Q1 2026, an estimated $9.79K.
  • Regencell Bioscience made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #1013 holding.
  • Vident Advisory first reported a position in Regencell Bioscience in Q3 2025 and has held it in 3 quarters since.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.